141 Infos zu Konstantin Matentzoglu

30 Aktuelle Nachrichten

— Konstantin Matentzoglu, CEO von Celonic, bezeichnet den Life Science Park Rheintal in der Mitteilung als eine „einzigartige“ und ...

— ... breadth of services has been instrumental in creating tremendous value for our partners,” said Konstantin Matentzoglu, CEO, Celonic.

— Konstantin Matentzoglu, Celonic's Chief Executive Officer, said "With on-boarding of almost two decades of invaluable experience in optimization ...

— ... Gene space and enable us to offer large-scale ATMP GMP manufacturing from early 2022," said Konstantin Matentzoglu, CEO of Celonic.

1  Bilder zu Konstantin Matentzoglu

6 Profile in Sozialen Netzwerken

Konstantin Matentzoglu. CEO at Celonic Group. Basel · George Paratsokis. Brand Facilitator. Greece · Maria Georgitsis. Greece ...

CEO (Chief Executive Officer) at Celonic Group. See Konstantin Matentzoglu's contact information such as email address, phone number and linkedin page.

Created with Highcharts Date Count Number of publications by year Konstantin Matentzoglu Highcharts.com. Publication.

4 Team Members. Celonic has 4 executives. Celonic's current Chief Executive Officer is Konstantin Matentzoglu.

4 Hobbys & Interessen

— ... Konstantin Matentzoglu Department of Biology and Konstanz Research School Chemical Biology, University of Konstanz, Konstanz, ...

Konstantin Matentzoglu added: “I am excited about this truly enabling partnership, which goes beyond a loose out-licensing/co-marketing deal. Celonic and Fusion Antibodies engage together and will offer highly aligned services to provide a safe and efficient development approach to clients worldwide.”.

"For our biotech customers, each step towards market authorization boosts the valuation of their assets, and that's where Celonic's breadth of services has been instrumental in creating tremendous value for our partners," said Konstantin Matentzoglu, CEO, Celonic. "MilliporeSigma's Mobius® single-use ...

Monica Cubillos-Rojas,4 Konstantin Matentzoglu,3 Michael A Patton,1 Karin Wagner,5. Roselyn Coblentz,5 Debra L Ford,6 Deborah J G ...

1 Firmen-Beteiligungen

Konstantin Matentzoglu in Müllheim aus Deutschland ✓ hat ein Mandat bei Celonic AG - mit 4 Personen verbunden ✓ Letzte Änderung:

1 Business-Profile

Berufserfahrung, Kontaktdaten, Portfolio und weitere Infos: Erfahren Sie mehr – oder kontaktieren Sie Dr. Konstantin Matentzoglu direkt bei XING.

1 Persönliche Webseiten

Konstantin Matentzoglu works in the Biotechnology industry. About Konstantin Matentzoglu. Summary. Member Of The Supervisory Board @ Polpharma ...

4 Infos zur Ausbildung

von AG Uren · · Zitiert von: 204 — Anthony G Uren, Jaap Kool, Konstantin Matentzoglu, Jeroen de Ridder, Jenny Mattison, Miranda van Uitert, Wendy Lagcher, Daoud Sie, ...

with Angelman-like features. Gaurav V Harlalka,1 Emma L Baple,1 Harold Cross,2 Simone Kühnle,3. Monica Cubillos-Rojas,4 Konstantin Matentzoglu,3 Michael A Patton,1 Karin Wagner,5. Roselyn Coblentz,5 Debra L Ford,6 Deborah J G Mackay,7 Barry A Chioza,1. Martin Scheffner,3 Jose Luis Rosa,4 Andrew H Crosby1.

author = "Uren, {Anthony G} and Jaap Kool and Konstantin Matentzoglu and {de Ridder}, Jeroen and Jenny Mattison and {van Uitert}, Miranda and Wendy ...

Universität Konstanz

3 Dokumente

Basel, Switzerland (HQ). Stein, Switzerland. Heidelberg, Germany. Dr. Konstantin Matentzoglu. Private, JRS Group, Germany. ABOUT US.

von J Kool · · Zitiert von: 39 — Konstantin Matentzoglu;. Konstantin Matentzoglu. Authors' Affiliations: 1Division of Molecular Genetics, The Centre of Biomedical Genetics, ...

Authors: Anthony G. Uren,, Jaap Kool,, Konstantin Matentzoglu,, Jeroen de Ridder,, Jenny Mattison, Miranda van Uitert, Wendy Lagcher, Daoud ...

9 Wissenschaftliche Publikationen

Using the more traditional, but still powerful, approach of yeast-two-hybrid screening and affinity proteomics, Konstantin Matentzoglu and his ...

Summary p53 and p19ARF are tumor suppressors frequently mutated in human tumors. In a high-throughput screen in mice for mutations collaborating with ...

Mutation of HERC2 causes developmental delay with ... CUBILLOS-ROJAS, Konstantin MATENTZOGLU, ... HERC2 causes developmental delay with Angelman-like ...

UREN, Anthony G., Jaap KOOL, Konstantin MATENTZOGLU, Jeroen de RIDDER, Jenny MATTISON, Miranda van UITERT, Wendy LAGCHER, Daoud SIE, Ellen TANGER, Tony …

3 Allgemeine Veröffentlichungen

— Konstantin Matentzoglu, Celonic Switzerland A leading Greek pharma (ELPEN), our investment in R&D and a new Research Institute: a model ...

Dr. Konstantin Matentzoglu. Private, JRS Group, Germany. ABOUT US. GMP production. Employees: Heidelberg. 2. GERMANY. Basel. Development.

Anthony Uren · Jaap Kool · Konstantin Matentzoglu · Jeroen De Ridder · Anton Berns · Download · Document S1. Seven Figures and Six Tables.

5 Meinungen & Artikel

— CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and what makes ...

Konstantin Matentzoglu. Global citimpact: GM at Trenzyme GmbH. Profile · Groups · Memberships. Order By: Last Active, Most Members, Newly Created ...

— ... in the fight against this global pandemic, according to Konstantin Matentzoglu, CEO of Celonic, who was quoted in the press release.

BAU.DE - Forum - Estrich und Bodenbeläge : Kunstharzboden selbst verlegen

66 Webfunde aus dem Netz

— ... Gene space and enable us to offer large-scale ATMP GMP manufacturing from early 2022," said Konstantin Matentzoglu, CEO of Celonic AG.

Werdegang von Konstantin Matentzoglu aus Müllheim: Geschäftsführer der Celonic Deutschland Verwaltung GmbH, früher Geschäftsführer der Trenzyme GmbH.

Vollständige Informationen des Handelsregisters für Konstantin Matentzoglu in Müllheim (DE), Führungsaufgaben, Karriereverlauf, SHAB, Netzwerk,...

Sieh dir an, was Konstantin Matentzoglu (kmatentzoglu) auf Pinterest, der weltweit größten Sammlung von Ideen, entdeckt hat.

... Celonic AG The Biosimilars Group GmbH (i.L.) Renato Wirthner Josef Otto Rettenmaier Harald Klein Konstantin Matentzoglu aktuell vormals ...

Konstantin Matentzoglu – Ph.D. Generaldirektor, Celonic AG. MANAGEMENT. Cornelius Diamond. President. Dr. Diamond hält einen Doktortitel in Biophysik von ...

BioProcess Insider BPI Theater @ BIO Interviews — Tuesday Featuring Konstantin Matentzoglu, Chief Executive Officer of the CELONIC Group ...

Dr. Konstantin Matentzoglu, Celonic's Chief Executive Officer, said “With on-boarding of almost two decades of invaluable experience in optimization of ...

Celonic's CEO is Konstantin Matentzoglu. Other executives include Vikalp Mohan, COO; Harald Klein, CFO and 1 others. See the full leadership team at Craft.

In the press release, Konstantin Matentzoglu, CEO of Celonic, describes the Life Science Park Rheintal as a “unique” and “state-of-the-art” facility.

Celonic CEO: Konstantin Matentzoglu. CEO. Konstantin Matentzoglu. CEO Approval Rating Weigh In HeidelbergBaden-Württemberg.

Simone Kühnle, Ulrike Kogel, Sandra Glockzin, Andreas Marquardt, Aaron Ciechanover, Konstantin Matentzoglu, Martin Scheffner.

von J Kool · · Zitiert von: 39 — ... Daoud Sie, Jeroen de Ridder, Geoffrey Turner, Miranda van Uitert, Konstantin Matentzoglu, Wendy Lagcher, Paul Krimpenfort, Jules Gadiot, ...

von GV Harlalka · · Zitiert von: 83 — Gaurav V. Harlalka · Emma L. Baple · Harold Cross · Simone Kuhnle · Monica Cubillos-Rojas · Konstantin Matentzoglu · Michael A. Patton · Karin Wagner.

Dr Konstantin Matentzoglu. Supervisory Board Member, Polpharma Biologics Group. “We care about being respectful and transparent”. Konstantin Matentzoglu is ...

Der Celonic-Standort Heidelberg ist für die Mammutaufgabe bestens geeignet, wie Konstantin Matentzoglu erklärt: „Wir haben das Werksgelände am Heidelberger ...

Under the guidance of Trenzyme's Co-CEO Konstantin Matentzoglu the Konstanz (Germany)-based company also developed a comprehensive range of cell biological ...

— Dr Konstantin Matentzoglu, Celonic's chief executive, said: "With on-boarding of almost two decades of invaluable experience in optimization ...

— ... advanced therapies—drugs derived from genes, tissues or cells—by early next year, CEO Konstantin Matentzoglu said in a release.

— ... part of the short and long-term fight against the pandemic in Germany,” says Dr Konstantin Matentzoglu, CEO of the Celonic Group.